<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Depression.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Depression. Ann Arbor (MI): University of Michigan Health System; 2011 Aug. 23 p.  [7 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Depression. Ann Arbor (MI): University of Michigan Health System; 2005 Oct. 20 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Behavior therapy  (94.33); Bipolar disorder, unspecified  (296.80); Dysthymic disorder  (300.4); General physical examination  (89.7); Major depressive affective disorder, recurrent episode, unspecified  (296.30); Major depressive affective disorder, single episode, unspecified  (296.20); Unspecified episodic mood disorder  (296.90)"/><FieldValue Value="MSH: Antidepressive Agents ; Antidepressive Agents, Second-Generation ; Antipsychotic Agents ; Behavior Therapy ; Bereavement ; Bipolar Disorder ; Bupropion ; Central Nervous System Stimulants ; Citalopram ; Clinical Laboratory Techniques ; Cognitive Therapy ; Cyclohexanols ; Depressive Disorder ; Depressive Disorder, Major ; Diagnostic and Statistical Manual of Mental Disorders ; Drug Therapy ; Dysthymic Disorder ; Electroconvulsive Therapy ; Exercise ; Fluoxetine ; Hormone Replacement Therapy ; Lithium ; Marital Therapy ; Medical History Taking ; Medication Therapy Management ; Mental Disorders ; Mianserin ; Monoamine Oxidase Inhibitors ; Mood Disorders ; Neurotransmitter Uptake Inhibitors ; Paroxetine ; Patient Education as Topic ; Physical Examination ; Psychiatric Status Rating Scales ; Psychotherapy ; Questionnaires ; Referral and Consultation ; Seasonal Affective Disorder ; Serotonin Uptake Inhibitors ; Sertraline ; Substance Withdrawal Syndrome ; Suicide ; Thiophenes ; Thyroid Hormones ; Triazoles ; Valproic Acid "/><FieldValue Value="MTH: Affective Disorders ; Antidepressive Agents ; Bereavement ; Bipolar Disorder ; Bupropion ; Central Nervous System Stimulants ; Cognitive Therapy ; Depressive Disorder ; Dysthymic Disorder ; Electroconvulsive Therapy ; Exercise ; Hormone replacement therapy ; Hypericum perforatum ; Involutional Depression ; Lithium ; MAJOR DEPRESSIVE DISORDER ; Mental disorders ; Mirtazapine ; Monoamine Oxidase Inhibitors ; Norepinephrine re-uptake inhibitor ; Patient education (procedure) ; Patient referral ; Pharmacotherapy ; physical examination ; Psychotherapy ; Questionnaires ; Seasonal Affective Disorder ; Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) ; Serotonin Uptake Inhibitors ; Substance Withdrawal Syndrome ; Suicide ; Supportive care ; Valproic Acid "/><FieldValue Value="PDQ: fluoxetine ; sertraline ; supportive care/therapy ; valproic acid ; venlafaxine "/><FieldValue Value="SNOMEDCT_US: Anti-psychotic agent  (10784006); Anti-psychotic agent  (372482001); Antidepressant  (36236003); Antidepressant  (372720008); Behavioral therapy  (166001); Bipolar disorder  (13746004); Bupropion  (387564004); Bupropion  (96199001); Central stimulant  (349897000); Central stimulant  (372620004); Citalopram  (321986007); Citalopram  (372596005); Cognitive therapy  (183383008); Cognitive therapy  (228553007); Cognitive therapy  (228557008); Cognitive therapy  (304891004); Depressive disorder  (21061000119107); Depressive disorder  (35489007); Drug therapy  (416608005); Duloxetine  (407032004); Duloxetine  (407033009); Dysthymia  (78667006); Electroconvulsive therapy  (23835007); Episodic mood disorder  (94921000119107); Escitalopram  (395246009); Escitalopram  (400447003); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); f - Family history  (277652007); Fluoxetine  (372767007); Fluoxetine  (53640004); Hormone replacement therapy  (266717002); Hypericum perforatum  (51621002); Involutional depression  (321717001); Lithium  (321719003); Lithium  (85899009); Major depressive disorder  (370143000); Marital counseling  (68168001); Mental disorder  (74732009); Mianserin  (387565003); Mianserin  (96200003); Mild major depression  (87512008); Minor depressive disorder  (48589009); Mirtazapine  (108430001); Mirtazapine  (386847004); Moderate major depression  (832007); Monoamine oxidase inhibitor  (373281001); Monoamine oxidase inhibitor  (71770007); Mood disorder  (46206005); Norepinephrine re-uptake inhibitor  (407034003); Norepinephrine re-uptake inhibitor  (407035002); Paroxetine  (321963000); Paroxetine  (372595009); Patient education  (311401005); Patient referral  (3457005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Psychodynamic-interpersonal psychotherapy  (304822001); Psychotherapy  (75516001); Recurrent major depressive episodes  (268621008); Recurrent major depressive episodes  (66344007); Seasonal affective disorder  (247803002); Sertraline  (321958004); Sertraline  (372594008); Single major depressive episode  (268620009); Single major depressive episode  (36923009); Suicide  (44301001); Support  (243114000); Thyroid hormone  (18220004); Triazole  (426233002); Valproic acid  (13965000); Valproic acid  (387080000); Venlafaxine  (108432009); Venlafaxine  (372490001)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Depression, including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Major depressive disorder (MDD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dysthymia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minor depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seasonal affective disorder (SAD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mood disorders associated with a general medical condition &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bereavement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bipolar disorder &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To improve the early recognition and treatment of depression in the primary care setting &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To improve patient's understanding of depression and its treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To familiarize clinicians with appropriate treatment options, i.e., medication and psychotherapies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To identify when referral is indicated &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults with depressive disorders&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening and Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Use of Diagnostic and Statistical Manual of Mental Illness-IV (DSM-IV) criteria for diagnosis of major depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient Health Questionnaire (PHQ-9) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History (family history, history of prior manic or hypomanic episodes, substance abuse, and other comorbid disorders) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of severity, suicidal tendencies, and psychotic features &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory testing (not recommended routinely) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Supportive care&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Selective serotonin reuptake inhibitors (SSRIs)&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Citalopram &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Escitalopram &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fluoxetine &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Paroxetine &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Sertraline &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serotonin-2 antagonist/reuptake inhibitor: nefazodone &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serotonin/norepinephrine reuptake inhibitor (SNRIs)&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Venlafaxine &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Desvenlafaxine &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Duloxetine &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serotonin and alpha-2 receptor blocker: mirtazapine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Norepinephrine/dopamine reuptake inhibitor: bupropion &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Any psychotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interpersonal psychotherapy (IPT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cognitive behavioral psychotherapy (CBT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Marital therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing clinical assessment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatments for severe or refractory depression: antidepressant combination, lithium, thyroid hormone supplementation, antipsychotic medication, electroconvulsive therapy, stimulant medication, monoamine oxidase inhibitors (MAOIs), mood stabilizers, referral &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of side effects of therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Special considerations in adolescents and older patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;St. John's wort and management of withdrawal syndrome (controversial areas) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mortality rates by suicide &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depressive symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency and severity of relapses &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Outpatient visits and inpatient hospitalization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality from myocardial infarction and cerebrovascular accident (CVA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Direct and indirect costs (including direct patient care, time lost from work, and potential income loss due to suicide) associated with major depressive disorder &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The literature search for this update began with results of the literature search performed in 1997 to develop the initial guideline released in 1998 and the search performed in 2002 for the update released in 2004. The literature search for this update used keywords that were very similar to those used in the previous searches. However, instead of beginning the search with literature in 2002, the guideline team accepted the search strategy and results for the search performed through 12/31/06 for the Veterans Affairs/Department of Defense (VA/DoD) Clinical Practice Guideline for Management of Major Depressive Disorder (MDD).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search for this update was conducted prospectively on Medline using the major keywords of: depression, depressive disorders; clinical guidelines, controlled clinical trials, cohort studies; adults; English language, and published 1/1/07&amp;ndash;1/31/10. Terms used for specific topic searches within the major key words included: epidemiology, national cost of treatment (economics); spectrum of depression, seasonal affective disorder, dysthymia; screening for depression; screening for bipolar disorder; diagnosis; suicide risk assessment; patient education; exercise; pharmacotherapy and psychotherapy &amp;ndash; comparison and in combination; combinations of more than one pharmacologic agent; serotonin selective reuptake inhibition (citalopram, escitalopram, fluoxetine, paroxetine, sertraline); serotonin/norepinephrine reuptake inhibition (desvenlafaxine, duloxetine, mirtazapine, tricyclic antidepressants, venlafaxine); norepinephrine/dopamine reuptake inhibition (bupropion); serotonin-2 antagonist/reuptake inhibition (nefazodone, trazodone); St. John's wort (Hypericum Perforatum); maintenance on pharmacotherapy, continuation duration; withdrawal syndrome (paroxetine/Paxil, desvenlafaxine, venlafaxine); medication adherence; managing sexual side effects of pharmacologic agents; pregnancy and pharmacologic agents; breast feeding and pharmacologic agents; pharmacotherapy not included above; mindfulness based therapy; problem solving therapy; interpersonal psychotherapy, cognitive behavioral therapy, short-term or focal psychodynamic psychotherapy, marital therapy, psychotherapy, not included above; other treatment not included above; ongoing clinical assessment; medical comorbidity; alcohol abuse; panic (including generalized anxiety disorder or phobia); obsessive compulsive disorder; post-traumatic stress disorder; eating disorders and anorexia nervosa; partner violence; sexual assault; pregnancy (not included above); postpartum (not included above); and depression not included above. Specific search strategy available upon request.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The search was conducted in components each keyed to a specific causal link in a formal problem structure (available upon request). The search was supplemented with very recent clinical trials known to expert members of the panel. Negative trials were specifically sought. The search was a single cycle.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials&lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if randomized controlled trials were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drafts of this guideline were reviewed in clinical conferences and by distribution for comment within departments and divisions of the University of Michigan Medical School to which the content is most relevant: Family Medicine, General Medicine, General Obstetrics &amp;amp; Gynecology, and Psychiatry. The Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers endorsed the final version.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;em&gt;Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)&lt;/em&gt;&lt;/strong&gt;: The following guidance was current as of August 2011. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/depress.html&quot; title=&quot;UMHS Web site&quot;&gt;original guideline document&lt;/a&gt; for the most current version.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from NGC&lt;/strong&gt;: The following key points summarize the content of the guideline. Refer to the full text of the original guideline document for detailed information on diagnosis, treatment, and medications.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of recommendation (I-III) and levels of evidence (A-D) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Epidemiology&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Common. Depression is common, under-diagnosed, and under-treated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recurrent. Depression is frequently a recurrent/chronic disorder, with a 50% recurrence rate after the first episode, 70% after the second, and 90% after the third. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Care provider. Most depressed patients will receive most or all of their care through primary care physicians. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Depressed patients frequently present with somatic complaints to their primary care doctor rather than complaining of depressed mood &lt;em&gt;[C]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Mild major depression can be effectively treated with either medication or psychotherapy. Moderate to severe or chronic depression may require an approach combining medication and psychotherapy &lt;em&gt;[IIA]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Drug treatment&lt;/strong&gt;. 40%-50% of patients respond to the first antidepressant &lt;em&gt;[A]&lt;/em&gt;. No particular antidepressant agent is superior to another in efficacy or time to response. Choice is often guided by matching patients' symptoms to side effect profile, presence of medical and psychiatric co-morbidity, and prior response &lt;em&gt;[IIA]&lt;/em&gt;. Relative costs can also be considered because of the large selection of antidepressants available in generic form. Patients treated with antidepressants should be closely observed for possible worsening of depression or suicidality, especially at the beginning of therapy or when the dose increases or decreases &lt;em&gt;[IC]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Frequent initial visits&lt;/strong&gt;. Patients require frequent visits early in treatment to assess response to intervention, suicidal ideation, side effects, and psychosocial support systems &lt;em&gt;[ID]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Continuation therapy&lt;/strong&gt;. Continuation therapy (9-12 months after acute symptoms resolve) decreases the incidence of relapse of major depression &lt;em&gt;[IA]&lt;/em&gt;. Long-term maintenance or life-time drug therapy should be considered for selected patients based on their history of relapse and other clinical features &lt;em&gt;[IIB]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Education/support&lt;/strong&gt;. Patient education and support are essential. Social stigma and patient reluctance to accept a diagnosis of depression or enter treatment continue to be a problem &lt;em&gt;[IIC]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Generally should be performed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;May be reasonable to perform &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Generally should not be performed &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm is provided in the original guideline document for an overview of treatment for depression.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conclusions were based on prospective randomized controlled trials (RCTs) if available, to the exclusion of other data; if RCTs were not available, observational studies were admitted to consideration. If no such data were available for a given link in the problem formulation, expert opinion was used to estimate effect size.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recognition and accurate diagnosis of depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate treatment of depression, with accompanying improvement in patient mood and functioning &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate continuation and maintenance therapy to decrease the incidence of relapse of major depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost-effective prescription of antidepressant medications&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Subgroups Most Likely to Benefit&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Table 5 in the original guideline document includes patient profiles most likely to benefit from specific drugs.&lt;/p&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Side Effects Associated with Antidepressant Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Insomnia &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Akathisia (a syndrome characterized by muscle restlessness) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weight gain &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sexual dysfunction &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Refer to Table 5 in the original guideline document for side effect information for specific antidepressants as well as selected important drug interactions, pregnancy and lactation risk categories, and patients least likely to benefit from selected antidepressants.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Duloxetine is not to be prescribed ordinarily if concurrent heavy alcohol use and/or evidence of chronic liver disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Do not use bupropion (Wellbutrin) if history of seizure, head trauma, substance abuse, bulimia, anorexia or electrolyte disturbance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Paroxetine should be avoided in pregnancy due to evidence of fetal cardiac malformations (although recent studies question this finding). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Refer to Table 5 in the original guideline for drug combinations that should not be used, particularly combination of selected antidepressants with monoamine oxidase inhibitors (MAOIs). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Patient Resources" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;University of Michigan Health System. Depression. Ann Arbor (MI): University of Michigan Health System; 2011 Aug. 23 p.  [7 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1998 Jun (revised 2011 Aug)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="University of Michigan Health System - Academic Institution" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Depression Guideline Team&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Team Leaders&lt;/em&gt;: Thomas L. Schwenk, MD, Family Medicine; Linda B. Terrell, MD, General Medicine&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Team Members&lt;/em&gt;: R. Van Harrison, PhD, Medical Education; Amy L Tremper, MD, Obstetrics &amp;amp; Gynecology; Marcia A. Valenstein, MD, Psychiatry&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Consultant&lt;/em&gt;: Jolene R. Bostwick, PharmD, College of Pharmacy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Guidelines Oversight Team&lt;/em&gt;: Connie J. Standiford, MD; Grant M Greenberg, MD, MHSA, MA; R. Van Harrison, PhD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The University of Michigan Health System endorses the Guidelines of the Association of American Medical Colleges and the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Disclosure of a relationship is not intended to suggest bias in the information presented, but is made to provide readers with information that might be of potential importance to their evaluation of the information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Team Member; Relationship; Company&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Jolene R Bostwick, PharmD (None)&lt;br /&gt;&#xD;&#xA;R Van Harrison, PhD (None)&lt;br /&gt;&#xD;&#xA;Thomas L Schwenk, MD (None)&lt;br /&gt;&#xD;&#xA;Linda B Terrell, MD (None)&lt;br /&gt;&#xD;&#xA;Amy L Tremper, MD (None)&lt;br /&gt;&#xD;&#xA;Marcia A Valenstein, MD (None)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: University of Michigan Health System. Depression. Ann Arbor (MI): University of Michigan Health System; 2005 Oct. 20 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/depress.html&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Continuing Medical Education (CME) information is available from the &lt;a href=&quot;http://cme.med.umich.edu/iCME/depression/default.asp&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The Patient Health Questionnaire-2 (PHQ-2) and PHQ-9 forms are available in the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/depress/depress.pdf&quot; title=&quot;UMHS Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Beyond sadness. Ann Arbor: University of Michigan Health System; 2002. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.med.umich.edu/1info/fhp/practiceguides/depress.html&quot; title=&quot;UMHS Web site&quot;&gt;University of Michigan Health System Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on May 20, 1999. The information was verified by the guideline developer on June 17, 1999. This NGC summary was updated by ECRI on October 12, 2004. The updated information was verified by the guideline developer on October 22, 2004. This summary was updated by ECRI on August 15, 2005, following the U.S. Food and Drug Administration advisory on antidepressant medications. This summary was updated by ECRI on October 3, 2005, following the U.S. Food and Drug Administration advisory on Paxil (paroxetine). This summary was updated by ECRI on October 20, 2005, following the U.S. Food and Drug Administration advisory on Cymbalta (duloxetine hydrochloride). This NGC summary was updated by ECRI on December 16, 2005. This summary was updated by ECRI on May 31, 2006 following the U.S. Food and Drug Administration advisory on Paxil (paroxetine hydrochloride). This summary was updated by ECRI on November 22, 2006, following the FDA advisory on Effexor (venlafaxine HCl). This summary was updated by ECRI Institute on November 9, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This summary was updated by ECRI Institute on July 20, 2009 following the U.S. Food and Drug Administration advisory on Varenicline and Bupropion. This summary was updated by ECRI Institute on January 8, 2010 following the U.S. Food and Drug Administration advisory on Valproate sodium. This summary was updated by ECRI Institute on November 14, 2011. This summary was updated by ECRI Institute on April 16, 2012 following the updated U.S. Food and Drug Administration advisory on Celexa (citalopram hydrobromide). This summary was updated by ECRI Institute on July 10, 2013 following the U.S. Food and Drug Administration advisory on Valproate.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
